QIAGEN provides technologies and products for preanalytical sample preparation and linked molecular assay solutions. QIAGEN also supplies diagnostic kits, tests, and assays for human and veterinary molecular diagnostics.QIAGEN offers its sample and assay consumable products in kit form.
Glyphic Biotechnologies is a biotechnology company that develops a protein sequencing platform. While DNA can reveal biological insights, proteins provide the actual insights into the functions of our bodies. The company is in the process of developing a pioneering, next-generation protein sequencing platform that will empower researchers to acquire unprecedented insights into both biology and diseases.
NeuMoDx Molecular, Inc. operates as a molecular diagnostics company. The company develops solutions for molecular diagnostic (MDx) testing in hospital and clinical reference laboratories.
N-of-One Therapeutics provides cancer care services. Its team of clinicians and scientists works with a network of diagnostic laboratories, research institutions, and cancer experts to provide access to cancer research, medical science, and molecular diagnostic testing. The company conducts research to assess the standard of care and other diagnostic and treatment opportunities for various cancer types.
Parsagen Diagnostics is comprised of a team of passionate and driven leaders who have a proven ability to bring a product from conception through commercialization in multiple global markets. As they expand their presence in the US & abroad, they are looking for people who exhibit flexibility under pressure, who have a proclivity to seek & approach challenges with optimism and grit, and who can identify areas of need and contribute to their ultimate fulfillment.
ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation identification and discovery. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays.
STAT-Diagnostica focuses in the development of near-patient testing products for healthcare professionals, mainly for short turnaround time applications and critical care.
OmicSoft is recognized for its suite of cutting-edge software solutions that enable scientists and researchers to efficiently analyze and visualize their own data sets and compare them to massive volumes of publicly available ‘omics’ data sets – such as The Cancer Genome Atlas (TCGA) operated by the U.S. National Cancer Institute – and share results with colleagues. These solutions, which integrate enterprise access and cloud-based resources, are essential in addressing the rapidly growing need of researchers in discovery and translational research to manage, compare and share the massive volumes of data on DNA, RNA and other biological variables generated with next-generation sequencing (NGS) technologies.
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.
MO BIO Laboratories, Inc. provides DNA and RNA isolation and protein extraction tools. The company engages in developing and manufacturing new products for life science research. It also provides soil, stool, and microbial nucleic acid purification services. In addition, the company provides certifications and sterility assurance services to various plastic and medical device suppliers.
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.
PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.
CLC bio is the world's leading bioinformatics solution provider focusing on analyzing data from all major high-throughput sequencing machines, such as instruments coming from Illumina, Applied Biosystems (LIFE Technologies), Roche 454, Helicos, or Sanger.
Ingenuity Systems is a software platform that provides information services that enable enterprise customers to provide their researchers access to information through internal portals, search engines, other software, and workflow sources, thereby enabling life science researchers to search, explore, visualize, and analyze biological and chemical findings related to genes, proteins, and small molecules.
Drug Response Dx is based in Hennigsdorf, Germany and was founded in February 2012 by Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner and Dr. Joachim Rautter. The biomarker set is prevalidated; the biochemicals and test samples are present. The proof of concept in serums from RA patients is established.
Intelligent Bio-Systems was founded in 2005 by Drs. Steven J. Gordon and Jingyue Ju to commercialize an advanced DNA sequencing system. Dr. Gordon previously founded Intelligent Automation Systems, which was responsible for a number of key instrumentation solutions which helped to complete the Human Genome Project. Dr. Ju is one of the key inventors of fluorescent energy transfer dyes used in most electrophoresis-based sequencers.
AmniSure is a diagnostic test for ROM cleared by the FDA for marketing and is reimbursable under most U.S. state Medicaid plans. The product is also approved in other markets around the world. The AmniSure test is a one-step, minimally invasive test strip using proprietary technology to detect tiny quantities of amniotic fluid in vaginal discharge. Results are available in minutes at the point of care. Accuracy of the AmniSure test is documented in multiple clinical studies and approaches 99% - far superior to traditional methods.
Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation. This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples. We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results.
Cellestis is manufactures and markets QuantiFERON products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses using whole blood samples.
Ipsogen
Acquisition in 2011
Ipsogen is develops and markets diagnostic tests in the field of oncology worldwide. The company offers diagnostic kits and biomarkers. Its products are used in the diagnosis, prognosis, and monitoring of patients with leukemia.
ESE GmbH
Acquisition in 2010
ESE GmbH is a company that was acquired by Qiagen in 2010.
SABiosciences Corporation, founded in 1998, is a privately held biotechnology company. Their founders envisioned a new, more systematic approach to biological research in the post-genomic era. Today, they have developed a portfolio of research tools that merge the benefits of hypothesis-driven and discovery-based research.
DxS (now a Qiagen company) is a personalized medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. Working in partnership with pharmaceutical companies, DxS will support the development and sales of targeted cancer therapies by providing companion diagnostic products and services. Since its founding in 2001, DxS has experienced considerable growth and firmly established itself as a leader in companion diagnostics, having recently secured deals with leading healthcare companies such as Amgen, Boehringer Ingelheim, and AstraZeneca. In addition, DxS has an exclusive agreement with Roche Diagnostics for the global distribution of its diagnostic products. DxS has a portfolio of cancer mutation products including both diagnostic and assays for research use. The TheraScreen® range of CE-marked (IVD) diagnostic* kits can identify genetic tumor mutations that affect how patients respond to cancer therapies, thus enabling doctors to provide the most beneficial treatment. DxS currently produce two diagnostic kits, TheraScreen K-RAS and TheraScreen EGFR29. The TheraScreen: K-RAS Mutation kit is a companion diagnostic for Vectibix® (Amgen) and Erbitux® (Merck KGaA) for the treatment of colorectal cancer. DxS was acquired by Qiagen (NASDQ : QGEN) and continues to operate from the heart of Manchester’s Technology Quarter in the UK.
Explera s.r.l. engages in importing, manufacturing, and marketing products in the molecular biology field for research laboratories in Italy and internationally. It offers instrumentations for DNA sequencing; thermal cyclers; ultra-compact thermal cycling products; photo-documentation systems; small equipments, such as shakers and rotators, multi shakers, shakers-incubators and thermo-shakers, centrifuges and vortexes, thermostats, water baths, dry blocks, and magnetic stirres; centrifuges; and biohazard and PCR cabinets.
Corbett Life Science Pty., Ltd. designs, manufactures, and internationally distributes instrumentation systems for the life sciences. The company offers Rotor-Gene, a DNA amplification system; CAS-1200, a PCR setup robot; the CAS-4200 and CAS-4800 precision liquid handling workstations; X-tractor Gene, a nucleic acid extraction system; Palm-Cycler, a gradient thermal cycler with a palmtop computer interface; and CorProtocol, a reagent for DNA preparation on the X-tractor Gene system. It also offers Vapor-Lock, a PCR encapsulation barrier; high resolution melt, a instrumentation that provides acute thermal and optical precision, high speed data acquisition, and new software tools for data analysis used for gene scanning, sequence matching, genotyping, quantitative allelotyping, and quantitative DNA methylation analysis; and the Gel-Scan 3000, a automated DNA sequencer and fragment analyzer. In addition, the company provides automation for RNA/DNA extraction, liquid handling robotics, and real time DNA amplification and analysis to laboratories across the United States. It has operation in North America, South America, the United Kingdom, Europe, the Middle East, Africa, Asia, and Oceania. The company has a strategic partnership with Sigma-Aldrich. Corbett Life Science Pty. Ltd. was formerly known as Bio-Molecular Holdings Pty. Limited. Corbett Life Science Pty., Ltd. was founded in 1988 and is based in Sydney, Australia. It has operating units in Sydney and Brisbane, Australia; Cambridgeshire, the United Kingdom; and San Francisco, the United States. As of July 1, 2008, Corbett Life Science Pty., Ltd. operates as a subsidiary of Qiagen NV.
eGene
Acquisition in 2007
eGene, Inc. is a biotechnology company, engages in developing, manufacturing, and marketing analytical systems and reagents for the genotyping market. It uses capillary electrophoresis, microfluidics, reagents liquid handling, and automation technologies to create a DNA/RNA analysis system for biological materials and life sciences testing. The company offers HDA-GT12 genetic analyzer, which uses capillary electrophoresis-based technology for DNA/RNA separation. Its HDA-GT12 system is used to detect, quantify, identify, and characterize biological organisms, as well as to automate the routine and non-routine laboratory and industrial procedures.
Digene Corporation is develops, manufactures, and markets proprietary gene-based diagnostic tests for the screening, monitoring, and diagnosis of human diseases with a focus on women’s cancers and infectious diseases worldwide. The company primarily offers human papillomavirus (HPV) testing products, which are FDA-approved tests for the detection of HPV, are a reproducible, objective test for the primary cause of cervical cancer. Its primary product is The Digene HPV Test, a FDA-approved test for HPV, the primary cause of cervical cancer.
Genaco Biomedical Products
Acquisition in 2006
Genaco Biomedical Products, Inc. develops and markets medical genetic products and services in China. The company offers prenatal screening; neonatal screening; commercial kits for prenatal screening and diagnosis of common genetic diseases; cytogenetic equipment; molecular genetics equipment, such as gel boxes and power supplies; and general laboratory supplies. It distributes its products through distributors and medical genetic centers.
Gentra Systems
Acquisition in 2006
Gentra Systems, Inc. develops and markets nucleic acid purification reagents and instruments for clinical and clinical research laboratories. The company’s DNA and RNA purification products include Generation Kits, which provide DNA purification for small samples; Purescript kit that provides a non-toxic method for purifying RNA; Autopure ls instrument for processing samples, by purifying Puregene-quality DNA from blood samples; and Versagene RNA.
Shenzhen PG Biotech Co, Ltd., is a molecular biology company, engages in the development, manufacture, and marketing of research and clinic diagnosis reagents and instruments. Its integrated services include technical consultation, product introduction, and customer order upon request, as well as after-sale service. The company serves in the areas of scientific fields, including molecular biology, cell biology, genetics, microbiology, and management.
Nextal Biotechnologies Inc. provides products designed for experimental needs of crystallization. The company provides plates that have grease-free independent screwable crystallization supports.
artus GmbH is a biotechnology company specialized in the development, production and sale of diagnostic kits based on modern DNA analytical procedures. The main focus of these detection procedures is PCR and real-time PCR technology. The detection systems are mainly used in identifying infectious agents, in pharmacogenomics and in veterinary diagnostics.
Molecular Staging, Inc., a life sciences tool company, develops technologies for the detection and measurement of proteins and nucleic acids. It provides technologies for proteomics, genomics, pharmacogenomics, and diagnostics applications. The company’s products and services include protein microarrays analogous to the DNA microarray, enabling researchers to study multiple proteins; whole-genome amplification that allows DNA samples as resources, enabling researchers to return to them for new tests or confirmatory diagnoses; and multiplexed diagnostics that enable earlier detection of disease.
Xeragon is develops and markets products and services focusing on oligoribonucleotides (RNA). The company’s TOM-Amidite technology allows chemical synthesis of RNA and its siRNA technology helps in RNA synthesis and gene silencing. Xeragon’s products and services are used by RNA scientists in the fields of biopharmaceuticals, diagnostics, therapeutics, and structural studies.
Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.
Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.